Tang XL, Miao YD, Mi DH. Comment on “Outcomes of curative liver resection for hepatocellular carcinoma in patients with cirrhosis”. World J Gastrointest Oncol 2022; 14(1): 366-368 [PMID: 35116123 DOI: 10.4251/wjgo.v14.i1.366]
Corresponding Author of This Article
Deng-Hai Mi, MD, Chief Doctor, Dean, Professor, The First Clinical Medical College, Lanzhou University, No. 1 Donggang West Road, Chengguan District, Lanzhou 730000, Gansu Province, China. mi.dh@outlook.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jan 15, 2022; 14(1): 366-368 Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.366
Comment on “Outcomes of curative liver resection for hepatocellular carcinoma in patients with cirrhosis”
Xiao-Long Tang, Yan-Dong Miao, Deng-Hai Mi
Xiao-Long Tang, Yan-Dong Miao, Deng-Hai Mi, The First Clinical Medical College, Lanzhou University, Lanzhou 730000, Gansu Province, China
Xiao-Long Tang, The Second Department of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China
Deng-Hai Mi, Dean's Office, Gansu Academy of Traditional Chinese Medicine, Lanzhou730000, Gansu Province, China
Author contributions: Tang XL and Miao YD designed, performed research and analyzed data; Tang XL wrote the comment; and Mi DH revised the comment.
Supported byThe Special Plan for Condition Construction of Gansu Provincial Scientific Research Institutes, No. 20JR10RA432.
Conflict-of-interest statement: No conflict of interest exists in submitting this manuscript, and all authors approve the manuscript for publication. All the authors listed have approved the manuscript that is enclosed.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Deng-Hai Mi, MD, Chief Doctor, Dean, Professor, The First Clinical Medical College, Lanzhou University, No. 1 Donggang West Road, Chengguan District, Lanzhou 730000, Gansu Province, China. mi.dh@outlook.com
Received: June 21, 2021 Peer-review started: June 21, 2021 First decision: July 29, 2021 Revised: August 9, 2021 Accepted: December 25, 2021 Article in press: December 25, 2021 Published online: January 15, 2022 Processing time: 203 Days and 15.5 Hours
Abstract
The present letter to the editor is in response to the research “Outcomes of curative liver resection for hepatocellular carcinoma in patients with cirrhosis” by Elshaarawy et al in World J Gastroenterol 2021; 13(5): 424–439. The preoperative assessment of the liver reserve function in hepatocellular carcinoma (HCC) patients with cirrhosis is crucial, and there is no universal consensus on how to assess it. Based on a retrospective study, Elshaarawy et al investigated the impact of various classical clinical indicators on liver failure and the prognosis after hepatectomy in HCC patients with cirrhosis. We recommend that we should strive to explore new appraisal indicators, such as the indocyanine green retention rate at 15 min.
Core Tip: Inappropriate hepatectomy might result in liver failure and even death for hepatocellular carcinoma (HCC) patients with cirrhosis. The main highlight of our comment is to emphasize the urgency of discovering and confirming new markers before hepatectomy in HCC patients with cirrhosis.
